Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Daiichi Sankyo Company Limited (JP:4568)
:4568
Holding JP:4568?
Track your performance easily
4568 Stock Chart & Stats
Day’s Range― - ―
52-Week Range¥4,015.00 - ¥6,257.00
Previous CloseN/A
Volume4.34M
Average Volume (3M)N/A
Market Cap
$8.30T
Enterprise Value¥8.35T
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)33.1
Beta0.94
Next Earnings
Jan 31, 2025EPS Estimate
29.64Next Dividend Ex-Date
Mar 28, 2025Dividend Yield1.48%
Share Statistics
EPS (TTM)130.93
Shares Outstanding1,947,034,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥6,556.95Price Target Upside49.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Daiichi Sankyo Company News
PremiumCompany Announcements
Daiichi Sankyo Reports Robust Q3 Earnings Performance
Bulls Say, Bears Say
Bulls Say
Pipeline ExpansionDS continues to pursue Dato Dxd’s additional indications including 1L NSCLC in combination of anti-PD-L1/PD-1.
Regulatory ApprovalFDA has approved anticancer candidate Dato-DXd for breast cancer, which is considered a positive surprise by the market.
Stock ValuationDaiichi Sankyo is trading at an attractive valuation, with expectations of the company's EPS expanding over the next five years.
Bears Say
Clinical Trial ResultsDaiichi's shares have declined by about 1/3 since the company reported disappointing Ph2 data from the TROPION-Lung01 study.
Regulatory EnvironmentThe US has implemented price control measures for Medicare under Biden administration, DS anticipates this trend to continue under Trump.
Stock PerformanceDaiichi's shares have declined by about 1/3 since the company reported disappointing data from a lung cancer study.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
12.39% Mutual Funds
0.02% Other Institutional Investors
79.25% Public Companies and
Individual Investors
4568 FAQ
What was Daiichi Sankyo Company Limited’s price range in the past 12 months?
Daiichi Sankyo Company Limited lowest stock price was ¥4015.00 and its highest was ¥6257.00 in the past 12 months.
What is Daiichi Sankyo Company Limited’s market cap?
Daiichi Sankyo Company Limited’s market cap is $8.30T.
When is Daiichi Sankyo Company Limited’s upcoming earnings report date?
Daiichi Sankyo Company Limited’s upcoming earnings report date is Jan 31, 2025 which is today.
How were Daiichi Sankyo Company Limited’s earnings last quarter?
Daiichi Sankyo Company Limited released its earnings results on Oct 31, 2024. The company reported ¥32.23 earnings per share for the quarter, beating the consensus estimate of ¥24.525 by ¥7.705.
Is Daiichi Sankyo Company Limited overvalued?
According to Wall Street analysts Daiichi Sankyo Company Limited’s price is currently Undervalued.
Does Daiichi Sankyo Company Limited pay dividends?
Daiichi Sankyo Company Limited pays a Annually dividend of ¥30 which represents an annual dividend yield of 1.48%. See more information on Daiichi Sankyo Company Limited dividends here
What is Daiichi Sankyo Company Limited’s EPS estimate?
Daiichi Sankyo Company Limited’s EPS estimate is 29.64.
How many shares outstanding does Daiichi Sankyo Company Limited have?
Daiichi Sankyo Company Limited has 1,947,034,000 shares outstanding.
What happened to Daiichi Sankyo Company Limited’s price movement after its last earnings report?
Daiichi Sankyo Company Limited reported an EPS of ¥32.23 in its last earnings report, beating expectations of ¥24.525. Following the earnings report the stock price went down -0.638%.
Which hedge fund is a major shareholder of Daiichi Sankyo Company Limited?
Currently, no hedge funds are holding shares in JP:4568
---
Company Description
Daiichi Sankyo Company Limited
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.
---
4568 Company Deck
---
4568 Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a robust financial performance with significant revenue and profit growth, driven by strong product sales and successful patent settlements. However, slight downward adjustments in sales forecasts and potential financial uncertainties were noted.Read More>---
4568 Stock 12 Month Forecast
Average Price Target
¥6,556.95
▲(49.19% Upside)
Technical Analysis
Astellas Pharma
―
Chugai Pharmaceutical Co
―
Sumitomo Dainippon Pharma Co
―
Eisai Co
―
Takeda Pharmaceutical Co
―
Best Analysts Covering 4568
1 Year
1 Year Success Rate
1/4 ratings generated profit
1 Year Average Return
-10.50%
reiterated a buy rating 4 days ago
Copying Miki Sogi's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -10.50% per trade.
---